RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to rally immune system against tough lymphomas
Disease control Recruiting nowThis study is testing a combination of two drugs, epcoritamab and ibrutinib, for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. The goal is to find a safe and effective dose. One drug helps the body's own immune…
Matched conditions: RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Double-Punch immune therapy aims to stop Lymphoma's return
Disease control Recruiting nowThis early-stage study is testing a two-part treatment to prevent aggressive B-cell lymphoma from coming back after a stem cell transplant. Doctors take a patient's own immune cells, modify them to target cancer, and infuse them back. They then give a vaccine designed to boost th…
Matched conditions: RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Double-Punch combo trial aims to tame aggressive cancer
Disease control Recruiting nowThis study is testing a two-part treatment for Richter's syndrome, an aggressive cancer that develops from a slower-growing blood cancer. It combines a daily pill (zanubrutinib) with a one-time infusion of specially modified immune cells (CAR-T therapy) to attack the cancer. The …
Matched conditions: RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New bridge to a cancer cure: drug combo aims to get more patients to Life-Saving CAR-T
Disease control Recruiting nowThis study is testing a two-drug combination (golcadomide and rituximab) as a 'bridging therapy' for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to control the cancer and improve patients' health so they can qualify fo…
Matched conditions: RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC